The Duchess of Gloucester met with researchers and clinical triallists on a royal visit to our Belfast-Manchester Movember Centre of Excellence, where attempts to find new ways to tackle advanced prostate cancer are already showing exciting early results.
While most men survive prostate cancer, one man every hour dies from the disease. As Dying Matters Awareness Week begins, we join together with men confronting advanced prostate cancer to help everyone talk about the ultimate taboo and highlight the support on offer.
Research published today has discovered a far higher proportion of inherited DNA mutations in men with advanced prostate cancer than previously suspected, opening up new possibilities for targeted treatments.
To coincide with Dying Matters Week, we've launched a new section of our website full of practical tips and personal stories to help men with advanced prostate cancer - and the people closest to them - to prepare for the end of their life.
Why a walk to a local restaurant for a romantic meal was such a special moment for one couple dealing with prostate cancer.
With the overwhelming public response to Kurt Jewson's Facebook photo following prostate cancer treatment, we explain the rarity of the disease in men under 50 and why the symptoms are so difficult to spot.
After more than a year of back and forth between NICE and drugs manufacturers, a decision about routine access to two advanced prostate cancer drugs, abiraterone and enzalutamide, without prior chemotherapy is finally in sight.
It's almost a year since our Movember Centres of Excellence opened their doors for business. Here’s a roundup of what's happened so far.
Researchers find DNA in blood samples can determine when life-prolonging drug abiraterone has stopped working in men with advanced prostate cancer.
It’s not been a good week for men. Hot on the heels of two other disappointing decisions), NICE (the National Institute of Health and Care Excellence) has just announced their intention not to make enzalutamide routinely available to men with advanced prostate cancer who haven’t had chemotherapy.